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Background: People with active cancer are recognised as at risk of COVID-19 complications, but it is unclear
whether the much larger population of cancer survivors is at elevated risk. We aimed to address this by com-
paring cancer survivors and cancer-free controls for (i) prevalence of comorbidities considered risk factors
for COVID-19; and (ii) risk of severe influenza, as a marker of susceptibility to severe outcomes from epi-
demic respiratory viruses.
Methods:We included survivors (1 year) of the 20 most common cancers, and age, sex and general practice-
matched cancer-free controls, derived from English primary care data linked to cancer registrations, hospital
admissions and death registrations. Comorbidity prevalences were calculated 1 and 5 years from cancer diag-
nosis. Risk of hospitalisation or death due to influenza was compared using Cox models adjusted for baseline
demographics and comorbidities.
Findings: 108,215 cancer survivors and 523,541 cancer-free controls were included. Cancer survivors had
more diabetes, asthma, other respiratory, cardiac, neurological, renal, and liver diseases, and less obesity,
compared with controls, but there was variation by cancer site. There were 205 influenza hospitalisations/
deaths, with cancer survivors at higher risk than controls (adjusted HR 2.78, 95% CI 2.043.80). Haematologi-
cal cancer survivors had large elevated risks persisting for >10 years (HR overall 15.17, 7.8429.35; HR
>10 years from cancer diagnosis 10.06, 2.4740.93). Survivors of other cancers had evidence of raised risk
up to 5 years from cancer diagnosis only (HR >5 years 2.22, 1.313.74).
Interpretation: Risks of severe COVID-19 outcomes are likely to be elevated in cancer survivors. This should be
taken into account in policies targeted at clinical risk groups, and vaccination for both influenza, and, when
available, COVID-19, should be encouraged in cancer survivors.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)ira).
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As of 7 July 2020, the novel Coronavirus disease 2019 (COVID-19)
has been diagnosed in over 11.6 million individuals with more than
539,000 deaths reported worldwide [1]. Around 20% of individuals
contracting the virus are estimated to develop severe disease requir-
ing hospitalisation, with a high risk of mortality [2]. A key aspect of
managing the impacts of the pandemic is understanding who is vul-
nerable to experiencing severe outcomes, so that mitigationstrategies can be targeted at those most in need. Those under current
treatment for cancer were recognised early on as being a high risk
group[3], but the extent to which the much larger population of
medium- to long-term cancer survivors might be considered vulnera-
ble is unknown. In England alone, this group includes over 1.8 million
people [4].
Current guidance on who should be considered vulnerable has
been largely based on policies developed for previous epidemic respi-
ratory viruses, notably influenza. For example, vaccination against
influenza is only recommend for individuals under active treatment
for cancer and for up two years following some treatments and hae-
matological cancers[5], while longer-term cancer survivors with no
recent immunosuppressing treatment are not considered high-risk in
Research in context
Evidence before this study
Few data are available to date on how COVID-19 affects cancer
survivors. We searched PubMed with the keywords “influenza
cancer survivors” to identify studies that compared severe
influenza outcomes in cancer survivors and in a control group.
No study was identified.
Added value of this study
In this matched cohort study of routinely collected electronic
health records, we demonstrated raised risks of influenza hos-
pitalisation or mortality in survivors from haematological
malignancies for >10 years after diagnosis, and in survivors
from solid cancers up to 5 years after diagnosis.
Implications of all the available evidence
Cancer survivorship appears to be an important risk factor for
severe influenza outcomes, suggesting that cancer survivors
may also be at raised risk of poor COVID-19 outcomes. This
should be taken into account in public health policies targeted
at protecting clinical risk groups. Influenza vaccination should
be encouraged in this group, and may need to be extended to a
wider population of medium- to long-term cancer survivors
than currently recommended.
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Cancer Society [5,6]. Yet medium- to long-term cancer survivors
could plausibly be at raised risk of severe COVID-19 outcomes. Stud-
ies amongst women with breast cancer have found chemotherapy to
be associated with changes in immune parameters that did not
return to pre-treatment levels a year or more after end of treatment,
raising the possibility of a long-term weakened immune system in
cancer survivors [7,8]. In addition, cancer survivors have known
raised risks of heart disease[9], which is itself an emerging risk factor
for COVID-19 mortality [10]. One large UK study identified raised
risks of COVID-19 mortality in survivors of haematological malignan-
cies even several years after cancer diagnosis[11], but there is little
other evidence to date to inform policy around managing COVID-19
related risks in cancer survivors.
We therefore aimed to investigate whether cancer survivors are
likely to be a high-risk group for severe outcomes during the current
COVID-19 pandemic in two ways: first, by comparing the prevalence
of risk factors currently used to guide COVID-19 policy between site-
specific cancers survivors and cancer free controls; second, by com-
paring the risk of influenza hospitalisation or death between cancer
survivors and cancer free controls, as a way of exploring susceptibil-
ity to severe outcomes from epidemic respiratory viruses.
2. Methods
This study is reported as per the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) guideline (Supple-
mentary Checklist S1).
2.1. Study design and data sources
We carried out a population-based cohort study amongst 1-year
survivors of the 20 most common site-specific cancers matched to
cancer-free controls. We used primary care data from Clinical Prac-
tice Research Datalink (CPRD GOLD)[12] linked to national data on
hospital admissions from the Hospital Episode Statistics AdmittedPlease cite this article as: H. Carreira et al., Prevalence of COVID-19-re
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National Cancer Registration and Analysis Service (NCRAS)[14], death
registrations  including cause of death information  from the
Office of National Statistics mortality database, and postcode-based
index of Multiple Deprivation data [9]. CPRD GOLD comprises rou-
tinely collected clinical and administrative data from general practi-
ces in the UK that use Vision software and have chosen to
participate; approximately 7% of the UK population is included. Data
include Read-coded diagnoses and care events, drug prescriptions,
numerical measurements (e.g., height and weight), laboratory test
results (e.g. serum creatinine) and health risk factors (e.g. smoking
status). Secondary care diagnoses reported to the general practitioner
(GP) through discharge letters are typically recorded in the general
practice record if they are considered to affect the ongoing care of the
patient. Linked International Classification of Diseases, version 10
(ICD-10) coded HES APC and NCRAS data improve ascertainment of
diseases treated in secondary care [9]. Use of linked data restricted
our study to England and the study period covered by all linked data
sources, January 1 1990, to December 31 2015,.
2.2. Study population
Cohorts of adult cancer survivors (aged 18 years) were identified
for each of the 20 most common cancer sites (listed in Table 1), as in a
previous study [9]. Briefly, we used CPRD GOLD, HES APC, and NCRAS
to identify 1-year survivors of incident cancer diagnoses. Incident
diagnoses were defined as the earliest record of a malignant cancer
of interest amongst individuals with at least 1 year of follow-up
meeting CPRD internal quality control criteria prior to the diagnosis
(to ensure that the cancer was incident). The derivation of the final
analysis cohort is described in Supplementary Figure S1. Cancer sur-
vivors with missing data on smoking (5.5%), body mass index (13.0%),
or index of multiple deprivation (an area-based proxy for socioeco-
nomic status derived from the patient’s postcode; <0.1%) were
excluded from the cohorts. Older records were more likely to be
excluded, as completeness of lifestyle information improved when
the Quality and Outcomes Framework was introduced in 2004 [12].
Cancer survivors were followed up from 1 year after diagnosis (index
date) and matched on age (§3 years), sex, and general practice to 5
controls with no history of cancer and at least 2 years of follow-up
prior to the index date of the matched cancer survivor (since cancer
survivors had to have one year of follow-up before and after the date
of cancer diagnosis to be included). Cancer survivors were eligible to
be selected as controls until the date of the incident cancer.
2.3. Outcome and covariates
The main outcome for the study was influenza hospitalisation or
death, identified using ICD-10 codes in HES APC and ICD-9 and ICD-
10 codes in ONS mortality data (codes available in Supplementary
Table S1). For the primary analysis, we counted hospitalisations with
a primary diagnosis of influenza, and deaths with an underlying
cause of influenza. In a sensitivity analysis, we broadened the defini-
tion to include hospitalisations/deaths with any code for influenza
present.
Age and sex were matching factors. Other covariates were index
of multiple deprivation quintile, smoking status (never, former, cur-
rent smoker), and common comorbidities identified a priori as of
potential importance in determining risk of severe COVID-19 out-
comes, namely asthma, chronic respiratory disease (other than
asthma), chronic heart disease, chronic liver disease, chronic neuro-
logical disease, chronic kidney disease, diabetes, obesity, sickle cell
disease and splenectomy. Other causes of immunosuppression were
not included due to overlap with cancer and its treatment. In a sec-
ondary analysis we also described the total number of comorbidities
(0 vs 1 vs 2 comorbidities from the aforementioned list). Full
lated risk factors and risk of severe influenza outcomes in cancer
th records data, EClinicalMedicine (2020), https://doi.org/10.1016/j.
Table 1
Characteristics of the patients included in analyses.
Cancer survivors Comparison group
Number (%) 108,215 (100) 523,541 (100)
Cancer site, N (%)
Bladder 7712 (7.13) 
Breast 25,633 (23.69) 
Cervix 1209 (1.12) 
Central nervous system 906 (0.84) 
Colorectal 14,216 (13.14) 
Gastric 1507 (1.39) 
Kidney 2197 (2.03) 
Leukaemia 3419 (2.03) 
Liver 554 (0.51) 
Lung 5369 (4.96) 
Malignant melanoma 7098 (6.56) 
Multiple myeloma 1843 (1.70) 
Non-Hodgkin lymphoma 4423 (4.09) 
Oesophagus 1794 (1.66) 
Oral cavity 1584 (1.46) 
Ovary 2710 (2.50) 
Pancreas 864 (0.80) 
Prostate 20,709 (19.14) 
Thyroid 1028 (0.95) 
Uterus 3440 (3.18) 
Years from index date to end
of follow-up
Mean (SD) 5.7 (4.7) 7.0 (4.7)






Age at index date (years)
Mean (SD) 66.1 (13.3) 66.0 (13.2)
Median (IQR) 67.0 (58.0, 76.0) 67.0 (58.0, 76.0)
Age at index date (years)
1839 4028 (3.7) 19,208 (3.7)
4059 27,029 (25.0) 131,049 (25.0)
6079 60,347 (55.8) 293,080 (56.0)
>=80 16,811 (15.5) 80,204 (15.3)
Gender
Men 51,541 (47.6) 245,760 (46.9)
Women 56,674 (52.4) 277,781 (53.1)
IMD quintile
1 (least deprived) 19,334 (17.9) 94,233 (18.0)
2 21,439 (19.8) 103,694 (19.8)
3 20,649 (19.1) 99,684 (19.0)
4 23,114 (21.4) 111,768 (21.3)
5 (most deprived) 23,679 (21.9) 114,162 (21.8)
Previous vaccination at index date
Influenza 72,924 (67.4) 322,908 (61.7)
Pneumococcal 48,953 (45.2) 224,496 (42.9)
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2.4. Statistical analysis
Prevalence of COVID-19 related risk factors in cancer survivors and con-
trols: amongst cancer survivors and controls alive and under follow-up
in CPRD GOLD at the index date (i.e. 1 year after cancer diagnosis for
cancer survivors) and 4 years later (5 years after diagnosis), we calcu-
lated the proportion with each morbidity of interest for all cancers com-
bined and individual cancer sites. The numerator included those with
any history of the relevant comorbidity at the given time point, except
for obesity, which was classified based on the most recent body mass
index (BMI) measure available at that time point.
Risk of influenza hospitalisation and mortality in cancer survivors
and controls: Individuals were followed up from the index date until
the earliest occurrence of the outcome, death without the outcome,
or end of study period. Follow-up was not censored at the end of data
collection in CPRD GOLD because the main analysis did not requirePlease cite this article as: H. Carreira et al., Prevalence of COVID-19-re
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hazards models with time since index date as the timescale, initially
accounting only for matching factors (i.e. age at index date, sex, and
general practice) through stratification by matched set and then addi-
tionally adjusting for the presence of risk factors at the index date (for
this analysis obesity was classified at the cancer diagnosis date since
weight measures in the year following cancer diagnosis may be
unstable). We examined the role of time since cancer diagnosis, by
fitting a time-updated variable indicating time of cancer survivorship
(1 to <5, 5 to <10, and 10 years since diagnosis, vs control group).
Since haematological malignancies directly affect the immune
system and treatments may have long-term immune consequences,
we stratified results by haematological versus other cancers by fitting
a three-level cancer survivorship variable. Due to limited power, we
did not break cancer sites down further. In a post hoc analysis, the
exposure variable included each haematological malignancy sepa-
rately (leukaemia, non-Hodgkin lymphoma, multiple myeloma) and
four groups of solid cancers (i.e. breast, gastrointestinal, genitouri-
nary, others); Wald tests were used after model estimation to test
the null hypothesis of heterogeneity of effect amongst subgroups.
As a secondary analysis, we explored mediation of any raised risk
of the primary outcome by development of recognised risk factors
during follow-up, by adjusting for time-updated risk factor variables
(taking the value “000 until the risk factor is first present, and “100 after-
wards). This analysis was additionally censored at the end of follow-
up in CPRD GOLD, since it relies on post-baseline primary care data.
Patients with missing data on BMI, smoking or deprivation were
excluded from the cohorts (see above), therefore all models were
based on complete case analyses. Multiple imputation was not used,
as the missingness was considered likely to be not at random in the
primary care setting [15,16], and complete case analysis minimises
bias in this situation, providing missingness is conditionally indepen-
dent of the outcome [17].
Sensitivity analyses: We conducted two main sensitivity analyses.
First, we broadened our definition of the outcome to include influ-
enza recorded anywhere in the hospitalisation or death record, to
account for the possibility of differential prioritisation of influenza
codes between cancer survivors and controls. Second, we adjusted
for time-updated influenza vaccination status and ever receipt of a
pneumococcal vaccine, as cancer survivors may be more likely to
receive influenza and pneumococcal vaccinations than general popu-
lation controls due to higher engagement with healthcare, or vacci-
nation indicated by immunosuppression following cancer and its
treatment, which may protect against influenza and influenza-related
death from secondary bacterial pneumonia. Influenza vaccinations
were considered current from the date of vaccination until the start
of the following influenza season in September. As vaccination
records were ascertained from primary care data, these analyses
were additionally censored at the end of CPRD follow up; we also re-
ran the primary model with this additional censoring in order to pro-
vide a similarly censored comparator for the sensitivity and media-
tion analysis models.
Ethics: This study was approved by the London School of Hygiene
& Tropical Medicine Ethics Committee (LSHTM Ethics Ref: 22,416)
and the Independent Scientific Advisory Committee for the Medicines
and Healthcare products Regulatory Agency database research
(20_082). Individual consent was not required for this study. CPRD
supplies anonymised data for public health research; individuals are
free to opt-out from having their data included in the database.
Role of funding source: The study funders had no role in study
design; in the collection, analysis, and interpretation of data; and in
the writing of the article.lated risk factors and risk of severe influenza outcomes in cancer
th records data, EClinicalMedicine (2020), https://doi.org/10.1016/j.
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This study included 108,215 cancer survivors, of which 9685 had
prior haematological malignancies, and 523,541 individuals with no
history of cancer (Table 1). Median (interquartile range [IQR]) age
was 67 (58, 76) in the cancer survivor and comparison group; 6674
(52.4%) and 277,781 (53.1%) of subjects were female, respectively.
3.1. Prevalence of COVID-19 related risk factors in cancer survivors and
controls
For all cancers combined, we observed higher absolute prevalence
of all risk factors for severe COVID-19 except for obesity and sickle
cell disease/splenectomy in 1-year cancer survivors, compared to the
cancer-free comparison group (Fig. 1, sickle cell/splenectomy not
shown as the prevalence was <0.2% in all groups). At 5-years after
diagnosis, cancer survivors overall had slightly higher prevalence of
all risk factors except heart disease and neurological conditions (dif-
ferences in prevalences ranging from 0.3% for diabetes and chronic
liver disease, to 1.8% for chronic kidney disease). Survivors of most
site-specific cancers also had raised prevalences of these risk factors,
with the magnitude varying by cancer site. The prevalence of obesity
was lower in cancer survivors than controls for several cancer sites,
but was substantially more common in survivors of uterus and kid-
ney cancers (prevalence difference at 5 years 20.1% [95%CI
19.820.5], and 8.5% [95%CI 8.18.8], respectively). Overall, 62.7% of
the cancer survivors had at least 1 of the included comorbidities
5 years after diagnosis, while 37.3% had two or more (Supplementary
Table S2). Comorbidity prevalences stratified by age and sex are pro-
vided in Supplementary Figure S2(a-h).
3.2. Risk of influenza hospitalisation and mortality in cancer survivors
and controls
205 people had the primary outcome (190 hospitalisations, 15
deaths) during a median follow-up time from the index date of
4.7 years in cancer survivors (IQR 1.98.4 years) and 6.2 years in con-
trols (IQR 3.39.9 years); follow-up exceeded 10 years for 19,273
(18%) cancer survivors and 128,132 (25%) controls. The risk of influ-
enza hospitalization or death was 2.7 times higher (95%CI 2.123.44)
in cancer survivors compared to people with no history of cancer
after accounting for matching factors only (Table 2). Control for other
covariates had little impact on the relative risk estimate (adjusted
HR=2.78; 95%CI 2.043.80).
Stratification by cancer group (haematological vs non-haemato-
logical) showed substantial differences. Haematological cancer survi-
vors had 15 times higher risk of a severe influenza outcome
compared to people without cancer (adjusted HR 15.17; 95%CI
7.8429.35), and further stratifying by time since cancer diagnosis,
the hazard ratio was 29.56 (95%CI 10.2085.66) for those 1 to
<5 years from diagnosis, falling to 9.56 (95%CI 4.3920.84) and 10.06
(95%CI 2.4740.93) for those 5 to <10, and 10+ years from diagnosis
respectively. Associations were smaller for non-haematological can-
cer survivors. The overall adjusted HR was 1.38 but compatible with
chance variation (95%CI 0.922.07). However, stratification by time
since diagnosis suggested a doubling of risk in those 1 to <5 years
from diagnosis (adjusted HR 2.22, 1.313.74) with no raised risk in
longer-term survivors.
3.3. Sensitivity, mediation and post-hoc analyses
Using hospitalisations and deaths with any mention of influenza
in the outcome definition led to more events being included (n = 320)
but a very similar pattern of results to the primary analysis (Supple-
mentary Table S3). In analyses that censored at end of CPRD follow-
up, fewer events were included (n = 167) but hazard ratios werePlease cite this article as: H. Carreira et al., Prevalence of COVID-19-re
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cancer survivors vs controls 3.88, 2.545.91, Supplementary Table
S4). Additional control for time-updated exposure to influenza and
pneumococcal vaccination led to similar but slightly stronger associa-
tions (overall HR 4.06, 2.656.24), while adjusting for mediators led
to slightly weaker associations (overall HR 3.27, 95%CI 2.125.04),
but in both cases patterns of results were similar. There was no
strong statistical evidence of a variation in the HRs amongst survivors
of leukaemia, non-Hodgkin lymphoma and multiple myeloma
(p = 0.08), or amongst survivors from the different solid cancers
(p = 0.42).
4. Discussion
Most comorbidities thought to be risk factors for poor COVID-19
outcomes were more prevalent in cancer survivors than cancer-free
controls, with variation by cancer site. After accounting for baseline
demographics, deprivation, smoking and risk factors distribution, the
risks of influenza hospitalisation and death were elevated >9-fold in
haematological cancer survivors compared with matched controls for
at least 10 years after diagnosis, and >2-fold in non-haematological
cancer survivors in the one to five years after diagnosis.
To our knowledge, this is the first large cohort study using pro-
spectively collected data to quantify the relative risk of severe influ-
enza outcomes in different groups of cancer survivors compared to
the general population, including stratification by time since diagno-
sis. The few previous studies in this area have reported high rates of
influenza amongst cancer survivors, consistent with our findings, but
have lacked a cancer-free comparison group [18-21]. Hermann et al.
investigated outcomes amongst patients with a history of cancer pre-
senting with influenza, and found no difference in mortality accord-
ing to haematological or non-haematological cancer type, or activity
of the cancer [18]. Our results showed considerably higher risks of
hospitalisation or death amongst haematological cancer survivors,
which could be consistent with the findings in Hermann et al. if hae-
matological cancer survivors are at increased risk of infection, but not
mortality once infected, compared to non-haematological cancer sur-
vivors. Other studies have investigated vulnerability to influenza
infection of any severity; two studies using administrative claims
data in South Korea found a high rate of claims for influenza amongst
both breast cancer survivors and survivors of childhood cancers
[19,20]. Similarly, Australian survey data found that a large propor-
tion (38%) of hematopoietic stem cell transplant survivors had influ-
enza-like illnesses in the time (median 5 years) since their transplant
suggesting potentially high vulnerability to infection, but there was
no control group or information on severity of infection [21].
Direct evidence on how COVID-19 affects cancer patients and sur-
vivors is immature. Early evidence from China and Italy suggested
that patients with history of cancer were overrepresented amongst
those admitted to hospital with COVID-19 [22,23]. The large UK
OpenSAFELY study found substantially raised risks of COVID-19 mor-
tality amongst individuals with prior haematological cancer persist-
ing for at least 5 years from cancer diagnosis, and smaller raised risks
for those with a history of non-haematological cancers up to 5 years
from diagnosis, consistent with our findings for influenza [11]. A
study from the COVID-19 and Cancer Consortium (CCC19) reported
high 30-day mortality amongst individuals with laboratory-con-
firmed COVID-19 and active or previous malignancy, finding high 30-
day mortality, even amongst those in remission, though active dis-
ease was a strong predictor of mortality [24]. Finally, a study that
focussed on patients with active cancer and COVID-19 found a non-
statistically significant increased risk of mortality in patients exposed
to chemotherapy 4 weeks prior to infection (OR=1.18, 95%CI
0.811.72), compared to cancer patients that did not receive chemo-
therapy, but the small numbers involved require further studies to
confirm these associations [25].lated risk factors and risk of severe influenza outcomes in cancer


























































































































































































































































































































































































































































































































































































































































































































































































































































































0 10 20 30 40 50
Prevalence
Chronic neurological conditions
1 year CS 1 year GPC 5 year CS 5 year GPC
CS > GPC (reasonable evidence) GPC > CS (reasonable evidence) weak evidence or no difference
Fig. 1. Prevalence of factors currently recognised as associated with high risk for severe COVID-19 outcomes in cancer survivors and controls at 1 and 5 years after diagnosis. Sickle
cell disease and splenectomy are not presented due to the rarity of the outcome.
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0 10 20 30 40 50
Prevalence
Chronic kidney disease
1 year CS 1 year GPC 5 year CS 5 year GPC
CS > GPC (reasonable evidence) GPC > CS (reasonable evidence) weak evidence or no difference
Fig. 1 Continued.
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Table 2
Relative risk of influenza hospitalisation or death in cancer survivors compared to non-cancer controls.
Associations adjusted for
matching factors only*
Associations adjusted for risk factors for severe
COVID-19 outcomes, smoking and IMD y
No. of individuals No. events#
(no. deaths)
PY at risk HR 95% CI HR 95% CI
No cancer history 523,541 205 (15) 3666,849 Ref Ref
All cancer survivors 108,215 85 (6) 620,144 2.70 2.12  3.44 2.78 2.04  3.80
15 years since diagnosis 108,215 46 (2) 326,913 4.16 2.94  5.88 4.34 2.86  6.59
510 years since diagnosis 59,938 27 (3) 201,332 2.15 1.44  3.21 2.37 1.53  3.66
>10 years since diagnosis 24,111 12 (1) 91,899 1.38 0.74  2.56 1.37 0.74  2.52
By cancer group
Haematological malignancies 9685 40 (3) 52,573 12.94 7.47  22.44 15.17 7.84  29.35
15 years since diagnosis 9685 20 (1) 29,072 22.21 8.34  59.17 29.56 10.20  85.66
510 years since diagnosis 5131 15 (2) 16,608 8.62 4.00  18.58 9.56 4.39  20.84
>10 years since diagnosis 1870 5 (0) 6894 9.90 2.46  39.78 10.06 2.47  40.93
All other cancers 98,530 45 (3) 567,570 1.50 1.09  2.05 1.38 0.92  2.07
15 years since diagnosis 98,530 26 (1) 297,841 2.47 1.61  3.80 2.22 1.31  3.74
510 years since diagnosis 54,807 12 (1) 184,724 1.05 0.62  1.80 1.08 0.58  2.01
>10 years since diagnosis 22,241 7 (1) 85,005 0.77 0.34  1.73 0.74 0.34  1.61
HR = Hazards ratio; PY = person-years at risk; Ref = reference category.
# Hospitalisations or deaths with influenza as the primary diagnosis/underlying cause.
* Cancer survivors and non-cancer controls were matched on age (within a 3-year age range), sex and primary care practice.
y Model adjusted for risk factors for poor COVID-19 outcomes (i.e. asthma and other chronic respiratory diseases, chronic neurological diseases, chronic liver
disease, chronic heart disease, chronic kidney disease, sickle cell disease or splenectomy, diabetes and obesity), smoking (former vs. current vs. never smokers),
and quintiles of relative deprivation measured by patient-postcode linked Index of Multiple Deprivation.
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nearly a quarter of whom were followed up for more than 10 years.
The size of our study enabled us to estimate prevalence of risk factors
for severe respiratory infection in site-specific cancer survivors for
the twenty most common cancer sites with good precision, and to
adjust our primary analysis of severe influenza outcomes for multiple
risk factors and stratify by type of cancer (haematological vs other).
Multiple validation studies have demonstrated the validity of CPRD
primary care data for measuring disease phenotypes including can-
cer, especially when combined with additional linked data sources
[26]. Our primary analysis was designed to be specific to hospitalisa-
tions and deaths caused by influenza, and a broader definition in sen-
sitivity analysis found similar results. A second sensitivity analysis
took account of time-updated vaccination status, which showed that
the associations we observed persisted, and in fact were stronger
after accounting for this apparent negative confounder.
There are some important limitations. We analysed severe influ-
enza in an attempt to inform COVID-19 policy but despite both being
infectious respiratory illnesses, it is not certain that risk factors for
severe influenza will have the same associations with COVID-19. Our
approach follows that of policy makers who have assumed parallels
with influenza in the absence of mature COVID-19 data [27]. As data
from the COVID-19 pandemic itself have started to flow, they have
largely confirmed a broad overlap between those at high risk for sea-
sonal influenza and for severe COVID-19 outcomes [11]. Another lim-
itation was that we did not have data on anti-cancer treatments, so
could not separate cancer survivors into those under active treatment
or not undergoing any treatment, which may be an important deter-
minant of risk. We only included cancer survivors at least one year
out from diagnosis, so it is likely that most patients with high-grade
malignancies would have completed primary treatment, but people
with low-grade tumours could conceivably have received anticancer
therapies some years after initial diagnosis, which could explain part
of the medium- to long-term increased risk of severe influenza;
linked cancer treatment data will be needed to investigate this fur-
ther. We cannot rule out that differences in the prevalence of risk fac-
tors between cancer survivors and controls five years post-diagnosis
may be due to increased contact with health services, particularly forPlease cite this article as: H. Carreira et al., Prevalence of COVID-19-re
survivors: A matched cohort study using linked English electronic heal
eclinm.2020.100656diseases such as chronic kidney disease which may be asymptomatic.
Our primary outcome combined influenza hospitalisations and
deaths but was dominated by the former; it is plausible that there
may be a lower threshold for hospitalisation in cancer survivors
which could have exaggerated the difference in risk of the primary
outcome between cancer survivors and controls, but is unlikely to
fully explain the large associations we observed. Finally, we had
some missing data on smoking and BMI data, and we excluded those
with missing data from the analysis; this is unlikely to affect our find-
ings under the assumption that the association between cancer survi-
vorship and severe respiratory outcomes is the same in people with
and without missing data, conditional on the covariates included in
the model. We have no reason to doubt this assumption, as recording
of BMI and smoking in primary care could be associated with cancer
survivorship but most likely is not associated with the risk of influ-
enza hospitalization or death.
The high prevalence of several established COVID-19 risk factors
in cancer survivors, and the increased risk of influenza hospitalisation
and death in survivors of haematological cancers even many years
from diagnosis, and in survivors from other cancers in the first five
years of survivorship, indicate a likely increased risk of severe
COVID-19 outcomes in these patient groups. Early direct evidence
from the COVID-19 pandemic appears to be consistent with this.
These findings suggest that cancer survivorship should be considered
a potentially important risk factor for severe COVID-19 outcomes in
public health policy. At present, while UK policy defines those with
active cancers and/or receiving treatments as high-risk for COVID-19
complications, the much larger overall population of cancer survivors
does not appear in either moderate or high-risk groupings[28]; these
risk groupings become increasingly important as general population
social distancing measures are eased and advice becomes more tar-
geted to those at risk.
Our results also have implications for preventive medicine in the
coming autumn and winter, when influenza and SARS-CoV-2 are
expected to coexist in the population. Improving influenza vaccina-
tion coverage amongst cancer survivors should be a priority, as the
vaccine is both effective and safe[29,30] but coverage has been
reported in the range of 50% to 76% amongst cancer survivors in thelated risk factors and risk of severe influenza outcomes in cancer
th records data, EClinicalMedicine (2020), https://doi.org/10.1016/j.
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may also be considered [33]. Of note, UK influenza vaccine guidance
focusses on cancer patients with active or recent disease or treat-
ment[5]; our findings suggest that a broader population of cancer
survivors should be considered as a high-risk group for influenza vac-
cination.
Future studies should focus on the risk of severe COVID-19 in can-
cer survivors, explore the role of comorbidities and prior exposure to
specific anti-cancer therapies, disaggregating data by cancer site
when possible.
In conclusion, survivors of haematological malignancies had sub-
stantially elevated risks of influenza hospitalisation or death persist-
ing for at least 10 years after cancer diagnosis, while risk was
doubled for survivors of other cancers for up to 5 years from diagno-
sis. In addition, cancer survivors had higher prevalence of several
chronic conditions associated with severe COVID-19, compared to
people with no history of cancer. This should be taken into account in
public health policies targeted at protecting clinical risk groups. Influ-
enza vaccination should be encouraged in this group, and may need
to be extended to a wider population of medium- to long-term cancer
survivors than currently recommended.
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